PP
TVRD

PDT Partners’s Tvardi Therapeutics TVRD Stock Holding History

PDT Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,364
Closed -$241K – 694
2023
Q2 		$241K Sell
2,364
-470
-17% -$64.7K 0.03% 489
2023
Q1 		$501K Buy
2,834
+1,797
+173% +$602K 0.07% 388
2022
Q4 		$401K Buy
1,037
+335
+48% +$127K 0.06% 429
2022
Q3 		$236K Sell
702
-426
-38% -$154K 0.04% 665
2022
Q2 		$371K Sell
1,128
-2,025
-64% -$710K 0.03% 689
2022
Q1 		$1.38M Buy
3,153
+108
+4% +$44.3K 0.12% 269
2021
Q4 		$1.33M Buy
3,045
+138
+5% +$69.3K 0.1% 303
2021
Q3 		$1.62M Buy
2,907
+851
+41% +$427K 0.12% 276
2021
Q2 		$1.06M Buy
2,056
+249
+14% +$158K 0.07% 370
2021
Q1 		$1.41M Sell
1,807
-214
-11% -$147K 0.1% 310
2020
Q4 		$1.1M Sell
2,021
-110
-5% -$57.7K 0.07% 310
2020
Q3 		$976K Buy
2,131
+248
+13% +$144K 0.06% 310
2020
Q2 		$1.16M Buy
+1,883
New +$1.04M 0.08% 260

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

PDT Partners's TVRD Position: Q3 2023 in Review

PDT Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 2,364 shares — an estimated $241K sold.

PDT Partners first reported a position in TVRD in Q2 2020 and held it in 13 quarters. The position peaked at $1.62M in Q3 2021. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • PDT Partners reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • PDT Partners sold 2,364 Tvardi Therapeutics shares in Q3 2023, an estimated $241K.
  • PDT Partners first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 13 quarters.
  • PDT Partners's Tvardi Therapeutics position peaked at $1.62M in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on PDT Partners's 13F filing for Q3 2023, filed 14 Nov 2023.